PL1723234T3 - VGLUT-specyficzne związki dsRNA - Google Patents

VGLUT-specyficzne związki dsRNA

Info

Publication number
PL1723234T3
PL1723234T3 PL05707623T PL05707623T PL1723234T3 PL 1723234 T3 PL1723234 T3 PL 1723234T3 PL 05707623 T PL05707623 T PL 05707623T PL 05707623 T PL05707623 T PL 05707623T PL 1723234 T3 PL1723234 T3 PL 1723234T3
Authority
PL
Poland
Prior art keywords
vglut
dsrnas
specific dsrna
dsrna compounds
specific
Prior art date
Application number
PL05707623T
Other languages
English (en)
Inventor
Clemens Gillen
Gregor Bahrenberg
Thomas Christoph
Eberhard Weihe
K -H Martin Schäfer
Florian Bender
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of PL1723234T3 publication Critical patent/PL1723234T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
PL05707623T 2004-03-10 2005-02-24 VGLUT-specyficzne związki dsRNA PL1723234T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102004011687A DE102004011687A1 (de) 2004-03-10 2004-03-10 VGLUT-spezifische dsRNA-Verbindungen
EP05707623A EP1723234B1 (de) 2004-03-10 2005-02-24 Vglut-spezifische dsrna-verbindungen
PCT/EP2005/001970 WO2005090571A1 (de) 2004-03-10 2005-02-24 Vglut-spezifische dsrna-verbindungen

Publications (1)

Publication Number Publication Date
PL1723234T3 true PL1723234T3 (pl) 2010-11-30

Family

ID=34960530

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05707623T PL1723234T3 (pl) 2004-03-10 2005-02-24 VGLUT-specyficzne związki dsRNA

Country Status (7)

Country Link
US (1) US20070117771A1 (pl)
EP (1) EP1723234B1 (pl)
AT (1) ATE471375T1 (pl)
DE (2) DE102004011687A1 (pl)
ES (1) ES2347574T3 (pl)
PL (1) PL1723234T3 (pl)
WO (1) WO2005090571A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112760276A (zh) * 2021-03-24 2021-05-07 扬州大学 一种柑橘原生质体的制备方法
CN114457045B (zh) * 2022-02-25 2023-07-14 中国人民解放军军事科学院军事医学研究院 抑制Slc2a1的RNAi腺相关病毒及其制备和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818391B2 (en) * 2000-07-25 2004-11-16 The Regents Of The University Of California Glutamate transporters
DE10128541A1 (de) * 2001-06-13 2003-02-20 Gruenenthal Gmbh Screening-Verfahren mit BNPI und DNPI
DE10133915A1 (de) * 2001-07-12 2003-02-06 Aventis Pharma Gmbh Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression

Also Published As

Publication number Publication date
EP1723234A1 (de) 2006-11-22
ATE471375T1 (de) 2010-07-15
US20070117771A1 (en) 2007-05-24
EP1723234B1 (de) 2010-06-16
DE102004011687A1 (de) 2005-10-13
ES2347574T3 (es) 2010-11-02
DE502005009757D1 (de) 2010-07-29
WO2005090571A1 (de) 2005-09-29

Similar Documents

Publication Publication Date Title
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
WO2007044084A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
RS20060320A (en) Substituted indazole-o-glucosides
SG130189A1 (en) Substituted indole-o-glucosides
AU2005302085A1 (en) Copper containing materials for treating wounds, burns and other skin conditions
WO2006024490A3 (en) Methods and compositions for the treatment of cell proliferation
WO2008098104A8 (en) Inhibitors of akt activity
UA87991C2 (en) Substituted indole-o-glucosides
MX2009013729A (es) Imidazopirazinas como inhibidores de proteina quinasa.
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
WO2005030121A3 (en) Compounds, compositions and methods
IL190796A0 (en) Compositions and their uses for gene therapy of bone conditions
SG170826A1 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
GEP20094845B (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
PL1654253T3 (pl) Podstawione pochodne 3-pirolidynoindolu
WO2007127273A3 (en) Methods and compositions for altering cell function
GEP20125511B (en) Mapk/erk kinase inhibitors
WO2006015258A3 (en) Methods and compositions related to argonaute proteins
WO2009158374A3 (en) Inhibitors of akt activity